Exclusive distribution agreement for Medis’ latest development Ladiva®, which will be commercialized by Biocodex Nordics in Finland, represents a new important milestone for both companies.
Ladiva® is a new medicine for symptomatic relief of minor spasms associated with menstruation in adult women. Ladiva® is a natural and medically-supported treatment for those who are concerned about their well-being during their periods. Maja Frelih, Managing Director Consumer Health Care Division at Medis explains:
Ladiva® is one of the strategic pillars on which we are striving to provide all women in Europe and beyond with a new solution, a natural yet effective and safe medication
Synergy has been recognized by Biocodex Nordics as Tessa Ahosalmi, General Manager at Biocodex Nordics, added:
Ladiva® is a great strategic fit with Biocodex products. In addition to our strong expertise and heritage in the microbiota therapy, our goal is to be an expert in women's health and well-being.
Martina Perharič, the Medis CEO, concluded:
It is both exciting and a privilege to begin a partnership with Biocodex and together make Ladiva® available to both patients and healthcare providers.
